Why the study?
Intravenous angiotensin II (Giapreza) was registered in the Czech Republic in 2023, prompting the need to summarize current scientific evidence on its efficacy and safety and provide an interdisciplinary position statement on its use in intensive care settings.
This position paper provides interdisciplinary consensus on the use of intravenous angiotensin II for refractory vasoplegic shock in Czech intensive care units.
Offers consensus guidance on angiotensin II for refractory vasoplegic shock; extends evidence synthesis to inform Czech ICU protocols.
Liv ppravek Giapreza obsahujc angiotensin II pro nitroiln podn je od roku 2023 registrovn v esk republice. lnek popisuje mechanismus inku liva, shrnuje souasnou vdeckou evidenci jeho innosti a bezpenosti a pin stanovisko mezioborovho panelu k pouvn angiotensinu II na pracovitch intenzivn pe, pedevm u pacient s refrakternm vazoplegickm okem. Text zskal ztitu esk spolenosti intenzivn medicny, esk spolenosti anesteziologie, resuscitace a intenzivn medicny a esk asociace akutn kardiologie.
No takes yet. Share an insight, caveat, or question.
Balík et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: